The VISION trial was a phase 3 international, open-label study that aimed to evaluate the efficacy of Lutetium-177 (177Lu)–PSMA-617, a radioligand therapy, in patients with metastatic castration-resistant prostate cancer (mCRPC). This type of cancer remains fatal despite recent advancements, and … Read More
prostate cancer
VISION Trial Summary: Lutetium 177 PSMA 617 for Metastatic Prostate Cancer
2021 VISION TRIAL Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer Prospective, open-label, randomized, international, phase 3 trial Objective: To evaluate Lutetium-177 (177Lu)-PSMA-617 a radioligand therapy along with standard care in Prostate-specific membrane antigen (PSMA) positive metastatic castration-resistant prostate cancer as compared … Read More